

# The Effect of Losartan on Cephalexin

NCT07300670

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1
<b>Sponsor</b>	Aleksi Tornio
<b>Enrollment</b>	12 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- written informed consent
  - years of age
  - good health
  - systolic blood pressure of at least 115 mmHg
  - all screening laboratory results (P-Krea, Pt-GFReEPI, P-Na, P-K, P-ALAT, P-AFOS, P-GT, B-PVK+T) acceptable; minor deviations from reference ranges are acceptable at the discretion of a physician-scientist with the exceptions of Pt-GFReEPI which must be at or above the reference limit and P-K which must be at or below the higher reference limit (Reference limits: Tyks Laboratories, Turku University Hospital)
- ... and 1 more (see full listing online)

### Exclusion (11)

- inability to provide written informed consent in Finnish
  - remarkable illness
  - confirmed or reasonably suspected allergy to cephalexin, amoxicillin, benzylpenicillin, phenoxymethylpenicillin, piperacillin, cefaclor, or cefamandole
  - confirmed or reasonably suspected severe delayed allergic reaction to any beta-lactam antibiotic
  - underweight (BMI less than 18.5 kg/m<sup>2</sup>)
- ... and 6 more (see full listing online)

## Locations (1 total)

---

Unit of Clinical Pharmacology, Turku University Hospital, Turku, Southwest Finland, Finland

---

<https://clinicaltrials.gov/study/NCT07300670>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).